Study | Yr | Study Design | Study Population | n | Age, Yrs | Sex, M/F | Diagnostic Criteria | Inclusion/exclusion Criteria | Disease Duration Reported | Wide DAS Range | Treatment Reported | Sample | Controls | Reference Values |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Berntzen, et al24 | 1988 | CS | Inpatients | 47 | NR | NR | ARA 1958 | Y | N | NR | N | Plasma | Y | Y |
Berntzen, et al25 | 1991 | CS | In/outpatients | 41 | Med 59 | 11/30 | ARA 1958 | Y | Y | NR | Y | Plasma, SF | Y | Y |
Brun, et al26 | 1992 | CS | NR | 43 | Med 57 | 4/39 | ARA 1958 | Y | Y | NR | Y | Plasma | Y | Y |
Brun, et al27 | 1994 | CS | Inpatients | 70 | Mean 60 | 22/48 | ARA 1958 | Y | Y | NR | Y | Plasma | Y | Y |
Burmeister, et al28 | 1995 | CS | NR | 11 | NR | NR | ARA, NR | N | N | NR | N | SF | Y | NA |
Madland, et al29 | 2002 | Longitudinal 5 yrs | Inpatients | 56 | Med 63 | 18/38 | ACR 1987 | N | Y | NR | Y | Plasma | N | Y |
Drynda, et al30 | 2004 | CS | NR | 23 | NR | NR | ACR 1987 | N | N | N | N | Plasma, SF | Y | N |
Longitudinal 3 mos | Biologic cohort | 40 | Mean 51 | 5/35 | ACR 1987 | N | N | N, DAS 28 6.26 ± 0.2 | N | Plasma | Y | N | ||
De Rycke, et al31 | 2005 | CS | NR | 40 | Med 45 | 12/28 | ACR 1987 | N | Y | Y | Y | serum, SF | Y | N |
Sunahori, et al32 | 2006 | CS | Inpatients | 17 | Mean 63 | 3/14 | ACR 1987 | N | N | N | Y | serum, SF | Y | N |
Hammer, et al33 | 2007 | CS | Early RA cohort | 145 | Mean 60 | 35/110 | ACR 1987 | Y | Y | Y | Y | Plasma | N | Y |
De Seny, et al34 | 2008 | CS | NR | 34 | Med 55 | 12/22 | ACR 1987 | N | Y | N, 86% DAS28 > 5.1 | Y | Plasma | Y | Y |
Hammer, et al35 | 2008 | Longitudinal 1 yr | NR | 61 | Mean 58 | 14/47 | ACR 1987 | N | Y | N, DAS28 4 ± 1.4 | Y | Plasma | N | Y |
Hammer, et al36 | 2010 | Longitudinal 10 yrs | Early RA cohort | 124 | Mean 51 | 30/94 | ACR 1987 | Y | Y | N | Y | Plasma | N | Y |
Andrés Cerezo, et al37 | 2011 | Longitudinal 3 mos | Early RA cohort | 43 | Mean 51 | 13/30 | ACR/EULAR 2010 | Y | Y | N, DAS28 5.3 ± 1.5 | Y | Serum | Y | N |
Hammer, et al38 | 2011 | Longitudinal 1 yr | Biologic cohort | 20 | Med 53 | 5/15 | ACR 1987 | N | Y | Y | Y | Plasma | N | Y |
García-Arias, et al39 | 2013 | CS | Single-center cohort | 60 | Mean 58 | 15/45 | ACR 1987 | Y | Y | Y | Y | Serum | N | Y |
Longitudinal 6 mos | Biologic cohort | 20 | Mean 64 | 2/18 | ACR 1987 | Y | Y | N | Y | Serum | N | Y | ||
Choi, et al40 | 2013 | Longitudinal 4–6 mos | Biologic cohorts | 170 | Med 57 | 32/138 | ACR 1987 | Y | N | N | Y | Serum | N | Y |
DAS: Disease Activity Score; CS: cross-sectional; NR: not reported; ARA: American Rheumatism Association; Y: yes; N: no; Med: median; SF: synovial fluid; NA: not applicable; ACR: American College of Rheumatology; DAS28: 28-joint DAS; EULAR: European League Against Rheumatism; RA: rheumatoid arthritis.